The size of the global articaine hydrochloride market was worth USD 1.37 billion in 2023 and is expected to reach USD 1.92 billion by 2028, which is anticipated to grow at a 7.07% CAGR from 2023 to 2028.
Articaine hydrochloride is a local anaesthetic used to control pain by blocking nerve signals in the body. Articaine is a form of local anaesthetic amide that is useful in dentistry. As per the FDI World Dental Federation report, more than 80% of people suffer from dental caries; such countries are the Asia Pacific, containing countries like Malaysia, Nepal, Indonesia, Bangladesh, and India. Besides, 40 to 59% of the population in China and Australia agonizes from dental caries.
Impact of COVID-19 on the global articaine hydrochloride market:
The Covid-19 pandemic has tremendously impacted the healthcare infrastructure with a growing focus on treating those suffering from COVID-19. This reduced the number of dental clinic visits and the postponement of non-essential procedures, limiting the risk of transmitting the virus. Unfortunately, this has dramatically decreased the sales in the articaine hydrochloride market, with a sharp drop in drug production due to lockdown and trade restrictions across the globe.
The growth of the global articaine hydrochloride market is likely to be driven by increased dental caries and other periodontal diseases.
Articaine hydrochloride is the most popular local anaesthetic in dentistry. The advancement of the dental anesthesia delivery system device and the innovative nature of the dental anesthesia industry propel the growth of the articaine hydrochloride market. Periodontal disease is one of the foremost dental conditions influencing human populations worldwide with high prevalence rates. Periodontal disease is more common in the Asia-Pacific. The growing awareness of preventive and corrective treatments is also one of the growth factors of this market. The articaine hydrochloride market is a new management system encouraging dental specialists to manage more effective practices and focus on better clinical care.
The articaine hydrochloride market is further expected to grow due to the growing focus on oral hygiene and rising awareness of aesthetic, preventive, and corrective treatments across the globe.
According to the Centers for Disease Control and Prevention (CDC), 13.2% of children aged 5 to 19 and 25.9% of adults aged 20 to 44 had untreated tooth decay between 2015 and 2018, and 85.9% of children aged 2 to 17 had a dental visit in 2018. Additionally, in 2019, 64.9% of adults aged 18 and older had a dental visit. According to the WHO, it is estimated that approximately 2.37 billion people suffer from dental caries that affect their permanent teeth. Furthermore, a recent publication reported that nearly 90% of Chinese adults suffered from periodontal disease of varying severity, of which more than 30% had severe periodontitis, including 43.55% in the age group of 65-74 years old. Hence, the rising number of dental caries drives the demand for articaine hydrochloride.
Articaine Hydrochloride is indicated for local, infiltrative, or conductive anesthesia in simple and complex dental procedures in adults and pediatric patients four years of age and older, making it a good choice for anesthesia. Articaine works as a better alternative to perform more efficient procedures and enable better clinical care. Successful research and development backed by clinical trials and advancements in dental anesthesia system devices will provide significant growth opportunities for the market. Additionally, increased use of articaine for dental surgeries and rising expenditure on dental treatments drive market growth.
Articaine hydrochloride is the most popular anaesthetic option across developed countries such as Germany, Italy, the USA, and Australia, among others, where it is used by approximately 97.5% of dentists. The market is also expected to be driven by the increased number of global dental surgeries. Periodontal disease is one of the major dental diseases affecting human populations worldwide, with high prevalence rates and surgical procedures. In Italy, the prevalence of periodontal disease will increase over time. In 2019, about 15.88 thousand Italians per 100,000. According to the CDC, the prevalence of periodontitis was 70.98% to 87.42% in the German population, with a significantly higher prevalence in men. According to the FDI World Dental Federation, more than 80.23% of people in Asia-Pacific, including India, Bangladesh, Nepal, Malaysia, and Indonesia, suffer from poor oral hygiene. Additionally, between 40.65% and 59.5% of the population in China and Australia suffer from dental disorders.
The prevalence of periodontal diseases is estimated to be 20 to 50% worldwide. In 2010, the global productivity loss due to severe periodontitis was estimated at US$54 billion per year. Furthermore, the prevalence of the periodontal disease will increase in the coming years due to the increased retention of natural teeth due to a significant reduction in tooth loss among the elderly population. All these factors will significantly impact the studied market during the forecast period.
However, high dental procedure costs and unfavorable reimbursement policies are expected to hamper the market growth. For instance, more than 90% of dental costs are out-of-pocket expenses for much of the population in APAC due to the lack of proper reimbursement policies, which will make it difficult for people to have dental care procedures. In addition, some popular local anesthetics other than articaine are prilocaine, lidocaine, mepivacaine, and bupivacaine, and their availability and use as alternative products are likely to hinder the market growth.
In addition, prices are not regulated with side effects, insufficient drug knowledge regarding the use of articaine hydrochloride, and the presence of significant and excessive expansion of pharmaceutical companies hampers the market expansion. The presence of a vast production capacity exerted pressure on prices. Generics have captured most of the market, and counterfeit products rise has limited market growth.
Market Size Available
2022 to 2028
2023 to 2028
By Application, End-User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
This research report on the global articaine hydrochloride market has been segmented and sub-segmented based on application, end-user, and region.
Articaine Hydrochloride Market - By Application:
Throughout the forecast period, the nerve block segment is estimated to be the fastest-growing segment of the articaine hydrochloride market. It is projected to grow at a healthy CAGR during the forecast period. A nerve block is the preferred mode of anesthesia for the dentist's removal of wisdom teeth and other dental procedures.
Articaine Hydrochloride Market - By End User:
In 2021, the dental clinics segment accounted for the most significant share in the global articaine hydrochloride market. This segment is expected to experience a healthy growth rate during the forecast period owing to the increasing number of dental clinics across the globe and preferred places by patients for treatment.
Articaine Hydrochloride Market - By Region:
In 2021, Europe articaine hydrochloride market accounted for the largest share of the global articaine hydrochloride market, followed by North America and the Asia Pacific. However, Asia Pacific is to witness the highest CAGR in the coming years. The European market growth can be attributed to dentists' increased use of articaine hydrochloride, the growing number of dental clinics, and the high incidence of dental caries. Italy and France are the high-revenue generating markets in the European region. According to the International Classification of Periodontal Diseases, approximately 52% of adults in France suffer from periodontal problems.
North American articaine hydrochloride market held a substantial share in the global market in 2021 due to high healthcare expenditures, well-developed medical facilities, and favorable reimbursement policies for dental care. Other fundamental factors contributing to the expansion of the market include increasing incidence of dental caries, periodontics, and oral cancer in the region, high rate of cosmetic surgeries, increase in soft tissue, and laser surgeries are driving the market. According to the CDC, in 2020, nearly half of 46% of adults over 30 had signs of periodontal disease. In addition, periodontal disease affected about 9% of adults in 2020.
The Asia-Pacific articaine hydrochloride market is expected to account for the highest market growth in the coming years. China is the largest producer of articaine hydrochloride and will dominate the regional market due to successful production and distribution to meet unmet market demand. In addition, countries like Australia, China, Japan, and India will grow due to the high adoption of new technologies, their use of dental applications, and the rapid growth in the geriatric population. According to a 2018 United Nations Population Fund statistical report, people aged 60 and over made up about 13.9% of the world's population that year. This figure would increase by around 22% by 2050.
The Latin American articaine hydrochloride market is expected to rise at a CAGR of 7% from 2022 to 2027.
The articaine hydrochloride market in the MEA region is forecasted to be worth USD 170 million by 2027.
KEY MARKET PARTICIPANTS:
Some of the prominent companies operating in the global articaine hydrochloride market profiled in the report are 3M, Anhui BBCA Pharmaceutical Co., Ltd., Dentsply Sirona, Inibsa Dental S.L.U., Jinan Chenghui Shuangda Chemical Co., Ltd, Jinan Ruixing Pharmaceutical Technology Co., Ltd, Manus Aktteva Biopharma LLP, Pfizer Inc., Pierrel S.p.A., Sanofi, Septodont, Siegfried AG and Sigma Aldrich.
RECENT MARKET HAPPENINGS:
The global articaine hydrochloride market size is predicted to value USD 1.92 billion by 2028 from USD 1.37 billion in 2023.
Based on the application, the nerve block segment led the articaine hydrochloride market in 2022.
3M, Anhui BBCA Pharmaceutical Co., Ltd., Dentsply Sirona, Inibsa Dental S.L.U., Jinan Chenghui Shuangda Chemical Co., Ltd, Jinan Ruixing Pharmaceutical Technology Co., Ltd, Manus Aktteva Biopharma LLP, Pfizer Inc., Pierrel S.p.A., Sanofi, Septodont, Siegfried AG and Sigma Aldrich are some of the notable players in the global articaine hydrochloride market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]